Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Treating Fields (EFE-P100) + Docetaxel in Stage IV NSCLC
NCT05661240Phase 3Unknown
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology
- Start
- Dec 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Jiangsu Healthy Life Innovation Medical Technology. Primary endpoint: Progression-free survival at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT05661240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661240.